Diligence Sprint
A time-boxed StarMap assessment of a target before the term sheet: adoption risk across the seven success factors, a clinical workflow reality-check, and the questions to put to the founders.
MedTech due diligence: the clinical adoption check your analysts can't do from a deck.
StarMap® tells you whether a MedTech venture will be adopted in clinical routine once the CE mark, the pilot and the reimbursement code are in place.
Technically strong. Well funded. Certified and compliant. And still,
75%
of venture-backed MedTech startups never return the investment.
Sources: Nelson (2025), MD+DI; TTi Health Research.
The enemy has a name
Approval Theater, priced into your term sheet.
The milestones your deal memo rewards, the CE mark, the first pilot, the reimbursement pathway, are exactly the ones that say nothing about adoption. A venture can hit all three and still never enter a physician's daily routine. StarMap prices in the milestone that actually decides the return.
Approval is the starting line. Adoption is the goal.
What you get
The third lens, next to technical and regulatory.
Your existing diligence answers whether the product works and whether it may be sold. StarMap answers whether it will be used, and by whom, on a normal Tuesday.
Portfolio scan
Score an existing portfolio with StarMap OS to see which companies carry hidden adoption risk, where support capital does the most good, and which are becoming the living dead.
Clinical judgment on call
A physician with ICU and department-lead experience as a standing advisor for board-level MedTech decisions, when the question is clinical and the stakes are financial.
A Diligence Sprint is scoped per target and a portfolio scan per portfolio, so we quote both in the screening call. Clinical judgment on call is invite only.
How a Diligence Sprint runs
Scoped to the deal, not to a retainer.
You bring the target and the timeline. We bring the framework, the engine and the physicians.
-
Step 1
Screening call
Fit, scope and timeline. If StarMap is the wrong tool for this deal, you hear it in this call.
-
Step 2
Assessment
The founders complete the structured StarMap assessment. StarMap OS scores it across the seven success factors.
-
Step 3
Physician review
EvoMed's experts, practicing physicians, review scores, clinical workflow claims and evidence, and write the risk hierarchy for this venture.
-
Step 4
Committee-ready report
Scores, risk hierarchy, founder questions and a call with the physician before you decide. Optional Navigator for the portfolio company after closing.
Documented, not claimed
Medical and business perspective, in one room.
Operators and data leaders on what changes when clinical judgment enters the strategic conversation.
"I appreciate working with Dr. Havkic. He consistently manages to bring together medical and business perspectives, and this holds true even with innovative tech topics like analytics."
Bettina GoernerChief Data Officer, Eterno
"I was impressed with the medical expertise of the EvoMed team and their ability to integrate it seamlessly into our business operations. Their consulting was invaluable in navigating the complex medical imaging diagnostics industry, making our products even more user-friendly and patient-safe."
Davor DadicDirector DIIT, Dedalus
Questions we get asked
In plain terms.
How is StarMap different from technical or regulatory due diligence?
Technical diligence tells you whether the product works. Regulatory diligence tells you whether it may be sold. StarMap tells you whether it will be used in clinical routine once both are true, and that is where most venture-backed MedTech companies actually fail. It is the missing third lens, not a replacement for the other two.
How fast can a Diligence Sprint be done?
It is scoped to your deal timeline. The founders complete a structured StarMap assessment, StarMap OS scores it, and a physician reviews the result and the underlying material. The screening call clarifies what is realistic for your closing date.
Can StarMap score companies already in our portfolio?
Yes. A portfolio scan scores every company with StarMap OS and shows which ones carry hidden adoption risk, where support capital does the most good, and which are drifting toward the living dead: growing, but never commercially viable.
What does the diligence report contain?
Scores across the seven success factors, the risk hierarchy for this specific venture, the clinical workflow reality-check, and the questions to put to the founders before you sign. Written for an investment committee, not for a clinician.
Diligence Sprint
See the adoption risk before you price the round.
One screening call clarifies whether StarMap adds a lens your diligence is missing. If it doesn't, we say so.
Companies, clinics and programs we have worked with
